发明名称 |
COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR |
摘要 |
The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer. |
申请公布号 |
US2014248262(A1) |
申请公布日期 |
2014.09.04 |
申请号 |
US201314020761 |
申请日期 |
2013.09.06 |
申请人 |
F. Hoffmann-La Roche AG ;Genentech, Inc. |
发明人 |
Sampath Deepak;Klein Christian;Fairbrother Wayne John |
分类号 |
A61K39/395;A61K31/496 |
主分类号 |
A61K39/395 |
代理机构 |
|
代理人 |
|
主权项 |
1. A method for the treatment of a cancer in a human in need thereof comprising administering to said human an effective amount of a GA101 antibody or 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof for one or more dosing periods, followed by co-administering an effective amount of said GA101 antibody and 2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazin-1-yl)-N-(3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenylsulfonyl)benzamide or a pharmaceutically acceptable salt thereof for one or more dosing periods. |
地址 |
Basel CH |